Use of platelet-rich plasma in rheumatic diseases
Yessirkepov M. Fedorchenko Y. Zimba O. Mukanova U.
January 2025Springer Science and Business Media Deutschland GmbH
Rheumatology International
2025#45Issue 1
Platelet-rich plasma (PRP) has gained increasing recognition as a promising therapeutic agent in managing rheumatic diseases. Conventional treatments, including nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs (DMARDs), primarily act on reducing inflammation but fail to address the underlying mechanisms of connective tissue degradation. PRP, an autologous preparation enriched with growth factors and bioactive molecules, is pivotal in modulating inflammation and fostering tissue regeneration. This review overviews the therapeutic potential of PRP across a spectrum of rheumatic diseases, such as osteoarthritis (OA), rheumatoid arthritis (RA), systemic sclerosis (SSc), and osteonecrosis. The regenerative capacity of PRP, driven by vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and transforming growth factor-beta (TGF-β), promotes tissue repair, reduces cartilage damage and improves joint function. Emerging evidence supports the efficacy of PRP in early-stage OA, demonstrating superior outcomes over traditional therapies like hyaluronic acid and glucocorticoids in terms of pain relief and functional improvement. Despite its benefits, PRP therapy is characterized by variability in treatment responses, with challenges in standardizing preparation protocols and treatment regimens. This review highlights the need for robust clinical trials to establish uniform treatment protocols, optimize patient selection, and evaluate the long-term clinical outcomes of PRP therapy in rheumatic diseases.
Osteoarthritis , Platelet-rich plasma , Rheumatic diseases , Rheumatoid arthritis , Systemic sclerosis
Text of the article Перейти на текст статьи
Department of Biology and Biochemistry, South Kazakhstan Medical Academy, Shymkent, Kazakhstan
Department of Pathophysiology, Ivano-Frankivsk National Medical University, Halytska Str. 2, Ivano-Frankivsk, 76018, Ukraine
Department of Rheumatology, Immunology and Internal Medicine, University Hospital in Kraków, Kraków, Poland
National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland
Department of Internal Medicine N2, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Department of Surgery and Anesthesiology-Intensive Care, Khoja Akhmet Yassawi International Kazakh-Turkish University, Shymkent, Kazakhstan
Department of Biology and Biochemistry
Department of Pathophysiology
Department of Rheumatology
National Institute of Geriatrics
Department of Internal Medicine N2
Department of Surgery and Anesthesiology-Intensive Care
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026